Amgen (AMGN) Q1 2025 10-Q Quarterly Report
Filed: May 2, 2025Period ending Mar 31, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR Amgen (AMGN) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on May 2, 2025 for the fiscal period ending Mar 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Amgen Q1 2025 10-Q Analysis
Management Discussion & Analysis
- • Revenue Prolia $1,099M, up 10% YoY from $999M
- • U.S. Prolia sales $720M up 10%, ROW $379M up 11%
- • Global Prolia volume growth 13%, net selling price down 5%
- • No profitability or margin data disclosed in this section
- • No cash flow or guidance updates mentioned in this excerpt
Risk Factors
- • New credit market risk triggered by COVID-19 and interest rate increases causing volatility and potential impairments in investment portfolio
- • Market risk materially updated: asset impairments possible from inflation, credit downgrades, illiquidity, geopolitical events affecting investment values
- • Regulatory risk: cash deposits exceed insured limits at multinational banks, risking access to uninsured funds if institutions fail
- • Operational risk near-term: potential delays accessing uninsured cash could affect liquidity and financial position
- • Financial risk: exposure to impairments and realized losses on investments due to market disruptions and interest rate fluctuations
Amgen Q1 2025 Quarterly FinancialsXBRL
Revenue
$8.1B
▲ +9.4% YoY
Net Income
$1.7B
▲ +1631.0% YoY
Operating Margin
14.5%
▲ +115bp YoY
Net Margin
21.2%
▲ +2275bp YoY
EPS (Diluted)
$3.20
▲ +1623.8% YoY
Operating Cash Flow
$1.4B
▲ +101.9% YoY
Source: XBRL data from Amgen Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Amgen Quarterly Reports
Get deeper insights on Amgen
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.